Skip to main content
OpenTrials
Completed

NCT Number: NCT04454697

Tissue Retractors for Radiation Therapy of Head and Neck Tumors

The rate of therapy-associated side effects during and after radiotherapy of head and neck tumors is essential. The most effective approach to reducing acute toxicity is to cut out healthy tissue from the radiation field. The distance between the tumor and normal tissue can be individually increased using personalized, 3D printer-based tissue retractors (GWR). Even the smallest geometric changes lead to a significant dose reduction in normal tissue and significant advantages for the patient.

The current randomized phase II study evaluates the use of GWR with regard to acute toxicity. In addition, quality of life, long-term toxicity as well as local control and overall survival 12 months after radiotherapy are evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hopsital Heidelberg

Heidelberg, 69120, Germany

About this study

The most effective approach to reducing acute toxicity after radiotherapy is to cut out healthy tissue from the radiation field. GWR can increase the distance between the tumor and normal tissue. Even the smallest geometric changes lead to a significant dose reduction in normal tissue and significant advantages for the patient. Adequate immobilization also reduces unwanted movements, especially of the tongue.

The GWR are manufactured as combinable modules according to the "modular principle". This improves reproducibility and flexibility and reduces development and manufacturing costs. The study is being conducted as a monocentric, prospective, randomized phase II study. A total of 34 patients who meet the inclusion criteria are examined for acute toxicity after radiotherapy of a malignant head and neck tumor. The primary goal of the study is to reduce acute toxicity through individual immobilization of the jaw and tongue. Secondary study goals are the evaluation of quality of life and long-term toxicity as well as local control and overall survival twelve months after radiotherapy. In both groups, radiation therapy is carried out in accordance with guidelines using image-guided radiotherapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of a malignant head and neck tumor
  • Clinical target volume of radiotherapy may include portions of at least one region: oral cavity; Upper jaw; Lower jaw; Oropharynx; Hypopharynx; large salivary glands
  • Indication for radiotherapy alone (postoperative or definitive)
  • Age ≥ 18 years
  • Karnofsky performance score ≥ 60
  • Completed wound healing after tumor resection
  • The patient's consent and written consent
  • Ability of the patient to assess the nature and scope as well as possible consequences of the clinical study
  • Adequate contraception in women of childbearing potential and in men

Exclusion criteria

  • Pre-radiation in the head and neck area
  • Multifocal, diffuse growing tumors
  • Inadequate regression of toxicities from previous therapies
  • Jaw clamp (cutting edge distance ≤ 2 cm)
  • Simultaneous systemic tumor therapy during radiation (especially chemotherapy and immunotherapy)
  • Indications that the participant is unlikely to adhere to the study protocol (e.g. lack of compliance)
  • Missing written declaration of consent

Treatment and study plan

tissue retractors

Device

Patients receive a tissue retractor to spare healthy tissue during the course of radiation

Primary outcomes

  1. Toxcicity

    Time frame: immediately after completin of Radiotherapy

    Number of grade III toxcicity events

Secondary outcomes

  1. Assesment of Quality of life: questionnaire

    Time frame: up to 12 month after completion of radiotherapy

    Changes of Parameters on the Core Quality of Life Questionnaire C30, scores 1 to 6 (best)

  2. Assesment of Quality of life: questionnaire

    Time frame: up to 12 month after completion of radiotherapy

    Changes of Parameters on the Core Quality of Life Questionnaire H&N35, scores 1 to 6 (best)

Sponsors and collaborators

Lead sponsor

University Hospital Heidelberg

Other

Registry information

Official study title

Geweberetraktoren für Die Strahlentherapie Von Kopf-Hals-Tumoren - Prospektive Randomisierte Phase-II-Studie

Acronym: GUARD

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Jul 1, 2020
Registry last updated
Nov 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.